Global BulletinAll NewsFDA Approval AlertWomen in Oncology
Expert InterviewsAround the PracticeBetween the LinesFace OffFrom All AnglesMeeting of the MindsOncViewPodcastsTraining AcademyTreatment Algorithms with the Oncology BrothersVideos
Conferences
All JournalsEditorial BoardFor AuthorsYear in Review
Frontline ForumSatellite Sessions
CME/CE
Awareness MonthNurse Practitioners/Physician's AssistantsPartnersSponsoredSponsored Media
Career CenterSubscribe
Adverse Effects
Brain Cancer
Breast CancerBreast CancerBreast Cancer
Gastrointestinal CancerGastrointestinal CancerGastrointestinal CancerGastrointestinal CancerGastrointestinal CancerGastrointestinal Cancer
Genitourinary CancersGenitourinary CancersGenitourinary CancersGenitourinary Cancers
Gynecologic CancersGynecologic CancersGynecologic CancersGynecologic Cancers
Head & Neck Cancer
Hematologic OncologyHematologic OncologyHematologic OncologyHematologic Oncology
InfectionInfection
Leukemia
Lung CancerLung CancerLung Cancer
Lymphoma
Neuroendocrine Tumors
Oncology
Pediatric Cancers
Radiation Oncology
Sarcoma
Screening
Skin Cancer & Melanoma
Surgery
Thyroid Cancer
Spotlight -
  • Radiation Oncology
  • Surgery
Adverse Effects
Brain Cancer
Breast CancerBreast CancerBreast Cancer
Gastrointestinal CancerGastrointestinal CancerGastrointestinal CancerGastrointestinal CancerGastrointestinal CancerGastrointestinal Cancer
Genitourinary CancersGenitourinary CancersGenitourinary CancersGenitourinary Cancers
Gynecologic CancersGynecologic CancersGynecologic CancersGynecologic Cancers
Head & Neck Cancer
Hematologic OncologyHematologic OncologyHematologic OncologyHematologic Oncology
InfectionInfection
Leukemia
Lung CancerLung CancerLung Cancer
Lymphoma
Neuroendocrine Tumors
Oncology
Pediatric Cancers
Radiation Oncology
Sarcoma
Screening
Skin Cancer & Melanoma
Surgery
Thyroid Cancer
    • Conferences
    • CME/CE
    • Career Center
    • Subscribe

Your AI-Trained Oncology Knowledge Connection!

scout
Advertisement

Psilocybin May Help Alleviate Cancer-Related Depressive Symptoms

January 9, 2025
By Michael P. Bogenschutz, MD
Commentary
Video

Psilocybin may help address a need for effective medication to aid those who have psychological challenges related to a serious cancer diagnosis.

A need to provide effective medication to aid patients with psychological challenges related to a serious cancer diagnosis may be addressed by psilocybin, according to Michael P. Bogenschutz, MD.

CancerNetwork® spoke with Bogenschutz, director of the NYU Langone Center for Psychedelic Medicine and professor of Psychiatry at NYU Grossman School of Medicine, about potential unmet needs that treatment with psilocybin-assisted psychotherapy (PAP) may reduce in the context of a pooled analysis of 2 phase 2 trials published in Nature Mental Health.

Bogenschutz began by highlighting a paucity of effective medicinal treatment to help patients manage psychological ailments associated with serious cancer diagnoses. He additionally detailed that although antidepressants can mitigate symptoms of depression, they have not been particularly effective in treating patients with cancer.

Describing the time after a serious cancer diagnosis as an adjustment period, Bogenschutz explained that PAP can treat those who would otherwise be incapacitated by psychological challenges. He further iterated that prior studies have shown how a single dose of psilocybin demonstrated lasting mitigative effects on depressive symptoms for weeks to months in patients with major depression. He concluded by expressing that patients under the influence of psilocybin may better come to terms with the reality of their cancer prognosis.

Efficacy findings from the pooled analysis study found that PAP was associated with improved anxiety (P = .0049), depression (P = .0007), interpersonal sensitivity (P = .0005), obsession-compulsion (P = .0002), hostility (P = .009), and somatization (P <.0001) among patients with cancer.

Transcript:

There are not any effective medications to help [patients with] psychological challenges presented by a serious cancer diagnosis. If [patients] have major depression, they can be treated with antidepressants. They can be treated with medicines for anxiety. The antidepressants do not appear to be particularly helpful in this population, and they do not address what the underlying cause is, which, in many cases, is [having] this existential crisis of one’s own possible or probable death in the near future.

In some ways, I tend to think about this situation as an adjustment reaction. [Patients have] a challenging situation, and they may become symptomatic [or] become incapacitated because of the psychological challenges. The psilocybin-assisted treatment, in some ways, acts like any other medication––to treat the symptoms. There are studies for major depression independent of a cancer diagnosis demonstrating enduring effects on depressive symptoms for weeks to months after a single dose of psilocybin.

In this population, one of the ideas behind how this works is that the experiences that [patients] have under the influence of psilocybin may help them better to come to terms with the reality of death and what that means, and to find some acceptance and meaning in the face of [a] challenging situation.

Reference

Petridis PD, Grinband J, Agin-Liebes G, et al. Psilocybin-assisted psychotherapy improves psychiatric symptoms across multiple dimensions in patients with cancer. Nat Mental Health. 2024;2:1408-1414. doi:10.1038/s44220-024-00331-0

Newsletter

Stay up to date on recent advances in the multidisciplinary approach to cancer.

Subscribe Now!
Recent Videos
Ongoing studies in kidney cancer aim to explore determinants of immune-related adverse effects and strategies for mitigating them.
Machine learning-based approaches may play a role in further understanding of how somatic alterations influence responses or resistance to therapy.
Related Content

Rezatapopt Yields Responses Across TP53 Y220C-Mutated Solid Tumor Types

Rezatapopt Yields Responses Across TP53 Y220C-Mutated Solid Tumor Types

Tim Cortese
September 16th 2025
Article

Experts discuss considerations for improving the care of patients with prostate, kidney, and bladder cancer in community-based practices at World GU 2025.

Episode 13: Perspectives on Optimizing Community Care at World GU 2025

Manojkumar Bupathi, MD, MS;Benjamin Garmezy, MD;Sam S. Chang MD, MBA;Jeff Yorio, MD
September 16th 2025
Podcast

3D Medical Illustration of Bone Tumor in Hip Joint | © rdkcho - © rdkcho - stock.adobe.com

Stereotactic Ablative Radiotherapy Achieves Local Control on Bone Metastases

Tim Cortese
September 16th 2025
Article

Man Up? The Truth About Men's Health After Cancer

Man Up? The Truth About Men's Health After Cancer

Daniel C. McFarland, DO;Christian J. Nelson, PhD
September 16th 2025
Podcast

FDA Approves 2 Additional Denosumab Biosimilars in Prior Indications

FDA Approves 2 Additional Denosumab Biosimilars in Prior Indications

Tim Cortese
September 16th 2025
Article

Navigating the Mental and Emotional Landscape of Cancer

Navigating the Mental and Emotional Landscape of Cancer

Ariana Pelosci
September 16th 2025
Article
Related Content

Rezatapopt Yields Responses Across TP53 Y220C-Mutated Solid Tumor Types

Rezatapopt Yields Responses Across TP53 Y220C-Mutated Solid Tumor Types

Tim Cortese
September 16th 2025
Article

Experts discuss considerations for improving the care of patients with prostate, kidney, and bladder cancer in community-based practices at World GU 2025.

Episode 13: Perspectives on Optimizing Community Care at World GU 2025

Manojkumar Bupathi, MD, MS;Benjamin Garmezy, MD;Sam S. Chang MD, MBA;Jeff Yorio, MD
September 16th 2025
Podcast

3D Medical Illustration of Bone Tumor in Hip Joint | © rdkcho - © rdkcho - stock.adobe.com

Stereotactic Ablative Radiotherapy Achieves Local Control on Bone Metastases

Tim Cortese
September 16th 2025
Article

Man Up? The Truth About Men's Health After Cancer

Man Up? The Truth About Men's Health After Cancer

Daniel C. McFarland, DO;Christian J. Nelson, PhD
September 16th 2025
Podcast

FDA Approves 2 Additional Denosumab Biosimilars in Prior Indications

FDA Approves 2 Additional Denosumab Biosimilars in Prior Indications

Tim Cortese
September 16th 2025
Article

Navigating the Mental and Emotional Landscape of Cancer

Navigating the Mental and Emotional Landscape of Cancer

Ariana Pelosci
September 16th 2025
Article
Advertisement
About
Advertise
CureToday.com
OncLive.com
OncNursingNews.com
TargetedOnc.com
Editorial
Contact
Terms and Conditions
Privacy
Do Not Sell My Personal Information
Contact Info

259 Prospect Plains Rd, Bldg H,
Monroe, NJ 08831

609-716-7777

© 2025 MJH Life Sciences

All rights reserved.